These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26314858)

  • 1. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
    Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
    Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERCC1 and ERCC2 variants predict survival in gastric cancer patients.
    Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY
    PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of genetic polymorphisms in DNA repair genes
    Alsagaby S; Ahmed AA; Rasheed Z; Althwab SA; Aljohani ASM; Alhumaydhi FA; Alhomaidan HT; Alkhamiss AS; Alkhowailed M; Alaqeel A; Alblihed MA; Alrehaili J; Fernández N; Abdulmonem WA
    Nucleosides Nucleotides Nucleic Acids; 2022; 41(5-6):530-554. PubMed ID: 35319340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.
    Li HY; Ge X; Huang GM; Li KY; Zhao JQ; Yu XM; Bi WS; Wang YL
    Asian Pac J Cancer Prev; 2012; 13(7):3465-9. PubMed ID: 22994779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients.
    Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Valdivia-Bautista J; Faus-Dáder MJ; Calleja-Hernández MÁ
    Pharmacogenomics J; 2019 Apr; 19(2):164-177. PubMed ID: 29662106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
    Puerta-García E; Urbano-Pérez D; Carrasco-Campos MI; Pérez-Ramírez C; Segura-Pérez A; Calleja-Hernández ; Cañadas-Garre M
    Surg Oncol; 2020 Dec; 35():388-398. PubMed ID: 33035787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
    BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer.
    Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX
    Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
    Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
    Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
    Ji M; Xu B; Jiang JT; Wu J; Li XD; Zhao WQ; Zhang HY; Zhou WJ; Wu CP
    Onkologie; 2013; 36(6):335-40. PubMed ID: 23774147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
    Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
    Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
    Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
    Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
    Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
    Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
    Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
    Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
    BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
    Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N
    BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.
    Shahnam A; Ridha Z; Wiese MD; Kichenadasse G; Sorich MJ
    Pharmacogenomics; 2016 Oct; 17(15):1725-1732. PubMed ID: 27636246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
    Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
    Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
    Geng R; Chen Z; Zhao X; Qiu L; Liu X; Liu R; Guo W; He G; Li J; Zhu X
    PLoS One; 2014; 9(12):e116027. PubMed ID: 25545243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.